← 홈

방광·요로상피

85개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 85개
AntibodystaleAstraZenecaPhase 2

Cohort 4/5 (Durvalumab, Durvalumab (Cohort 4/5))

Urothelial Carcinoma; Bladder Cancer · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Imfinzi (Durvalumab, Durvalumab (Imfinzi))

Muscle-invasive Bladder Cancer · Muscle-invasive Bladder Cancer

#Muscle-invasiveBladderCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab + Gem/Cis)

Biliary Tract Neoplasms; Gallbladder Cancer · Biliary Tract Neoplasms

#BiliaryTractNeoplasms#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
ADCBiologicstaleGenerate BiomedicinesPhase 1

GB-4362 (GB-4362)

Advanced Urothelial Cancer; Metastatic Urothelial Carcinoma · Advanced Urothelial Cancer

#AdvancedUrothelialCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstalePeking University Third HospitalPhase 2

Chemotherapy (Gemcitabine, Gemcitabine (Chemotherapy))

Muscle-Invasive Bladder Cancer (MIBC) · Muscle-Invasive Bladder Cancer (MIBC)

#Muscle-InvasiveBladderCancerMIBC#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleWest China HospitalPhase 3

Gemcitabine + Cisplatin（GC）+Toripalimab (Gemcitabine + Cisplatin（GC）+Toripalimab)

Urinary Bladder Neoplasms · Urinary Bladder Neoplasms

#UrinaryBladderNeoplasms#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 1

nivolumab (Opdivo, Gemcitabine/Cisplatin/Nivolumab)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 and nivolumab)

Urothelial Carcinoma; Urothelial Carcinoma Bladder · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
ADCBiologicstaleEli Lilly and CompanyPhase 1

LOXO-435 (LOXO-435)

Urinary Bladder Neoplasms; Neoplasm Metastasis · Urinary Bladder Neoplasms

#UrinaryBladderNeoplasms#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleWeill Medical College of Cornel…Phase 1

Naptumomab Estafenatox (Naptumomab Estafenatox)

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleSwiss Cancer InstitutePhase 2

durvalumab (Imfinzi, Neoadjuvant and adjuvant durvalumab)

Urothelial Cancer · Urothelial Cancer

#UrothelialCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleSeoul National University Hospi…Preclinical

atezolizumab (Tecentriq, Neoadjuvant atezolizumab)

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
ADCBiologicstalePfizerPhase 1

PF-08046876 (PF-08046876)

Advanced/Metastatic Solid Tumors; Bladder Cancer · Advanced/Metastatic Solid Tumors

#AdvancedMetastaticSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel)

Metastatic Urothelial Carcinoma · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
CGTBiologicstaleThe Affiliated Hospital of Xuzh…Phase 1

Recombinant oncolytic adenovirus injection solution of VT-101 (Recombinant oncolytic adenovirus injection solution of VT-101)

Non-muscle Invasive Bladder Cancer · Non-muscle Invasive Bladder Cancer

#Non-muscleInvasiveBladderCancer#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
ADCBiologicstaleFudan UniversityPhase 2

Observational Cohort (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (Observational Cohort))

Bladder Cancer; Metastatic Urothelial Carcinoma · Bladder Cancer

#BladderCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleJunshi BiosciencesPhase 3

JS001 (Toripalimab, Toripalimab (JS001 ))

Urinary Bladder Neoplasms · Urinary Bladder Neoplasms

#UrinaryBladderNeoplasms#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab Rezetecan Combined with Adebelizumab)

Muscle-Invasive Bladder Cancer (MIBC) · Muscle-Invasive Bladder Cancer (MIBC)

#Muscle-InvasiveBladderCancerMIBC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleChanghai HospitalPhase 2

TURBT (Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor, Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT))

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Tremelimumab monotherapy (Tremelimumab monotherapy)

Urothelial Bladder Cancer; Triple-negative Breast Cancer · Urothelial Bladder Cancer

#UrothelialBladderCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 3.1%임상시험 1상태 ACTIVE

4 / 5 페이지

← 이전다음 →